Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Moderna creates rare disease subsidiary Elpidera

    Moderna Therapeutics Inc. (Cambridge, Mass.) launched Elpidera LLC, a subsidiary that will use Moderna's mRNA therapeutics platform to develop treatments for rare diseases. Greg Licholai, former SVP of real-world and …

    Published on 5/12/2015
  • COMPANY NEWS: GSK, UNC partner in HIV, launch newco Qura

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of North Carolina partnered to establish a research center at the university's Chapel Hill, N.C., campus and launch newco Qura Therapeutics aimed at curing HIV …

    Published on 5/11/2015
  • COMPANY NEWS: Juno acquires manufacturing play Stage

    Juno Therapeutics Inc. (NASDAQ:JUNO) acquired cell therapy manufacturing company Stage Cell Therapeutics GmbH (Gottingen, Germany) to help produce its chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies.…

    Published on 5/11/2015
  • COMPANY NEWS: Management tracks

    Vaccine play PaxVax Inc. (Redwood City, Calif.) promoted Nima Farzan to CEO from COO; he will remain president. Farzan will replace Kenneth Kelly, who will remain a director.Patient networking company PatientsLikeMe Inc…

    Published on 5/11/2015
  • COMPANY NEWS: Pfizer, AM-Pharma in equity/option deal

    Pfizer Inc. (NYSE:PFE) purchased an equity stake in renal company AM-Pharma B.V. (Bunnik, the Netherlands) and obtained an exclusive option to acquire the remainder of the company. Pfizer can exercise the option when an…

    Published on 5/11/2015
  • COMPANY NEWS: Project Data Sphere tops first-year target

    Data-sharing consortium Project Data Sphere LLC said on Monday that it accrued comparator-arm clinical trial data from 26,000 patient lives, which surpassed the first-year target of 25,000 lives the not-for-profit set …

    Published on 5/11/2015
  • COMPANY NEWS: Alder fleshes out timeline for migraine candidate

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) gained $7.04 (23%) to $37.23 on Friday after spelling out milestones expected next half for migraine candidate ALD403 during its 1Q15 earnings call.Alder plans to begin a …

    Published on 5/8/2015
  • COMPANY NEWS: Amarin sues FDA on free speech grounds

    Amarin Corp. plc (NASDAQ:AMRN) filed a lawsuit against FDA seeking a judicial declaration that the agency's regulation prohibiting Amarin from providing "truthful and non-misleading information" to healthcare …

    Published on 5/8/2015
  • COMPANY NEWS: Bass revs up Revlimid challenge

    Hedge fund manager Kyle Bass filed a second inter partes review (IPR) challenging a patent covering Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG), the latest in a string of challenges.The Coalition for …

    Published on 5/8/2015
  • COMPANY NEWS: FDA lifts clinical hold on NeuroDerm's PD therapies

    NeuroDerm Ltd. (NASDAQ:NDRM) gained $1.24 (11%) to $12.62 on Friday after FDA lifted a clinical hold on its Parkinson's disease candidates ND0612H and ND0612L. The company plans to begin U.S. clinical trials next half.…

    Published on 5/8/2015
  • COMPANY NEWS: GSK's mepolizumab gets June 11 FDA panel

    FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on June 11 to discuss a BLA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for mepolizumab as maintenance therapy for patients with severe eosinophilic asthma. …

    Published on 5/8/2015
  • COMPANY NEWS: Management tracks

    Horizon Pharma plc (NASDAQ:HZNP) promoted Brian Beeler to EVP and general counsel from SVP legal and chief compliance officer. The company also named Tim Ayers VP and chief compliance officer. Ayers was a principal and …

    Published on 5/8/2015
  • COMPANY NEWS: Orexigen's Contrave closes gap with rivals

    Orexigen Therapeutics Inc. (NASDAQ:OREX) reported $11.5 million in net U.S. sales of obesity drug Contrave naltrexone/bupropion in 1Q15, its first full quarter on the market. The company had reported $6.5 million in …

    Published on 5/8/2015
  • COMPANY NEWS: Vertex gains despite mixed Orkambi briefing docs

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) gained $2.36 to $127.41 on Friday despite mixed comments by FDA reviewers on Orkambi, the company's combination of lumacaftor (VX-809) and Kalydeco ivacaftor, to treat cystic …

    Published on 5/8/2015
  • COMPANY NEWS: China's top court invalidates Lipitor patent

    China's Supreme People's Court ruled invalid a patent covering crystalline formulations of Lipitor atorvastatin from Pfizer Inc. (NYSE:PFE), preventing it from suing generic makers and opening the door to additional …

    Published on 5/7/2015
  • COMPANY NEWS: Gilead shareholders vote against price disclosure proposal

    Shareholders in Gilead Sciences Inc. (NASDAQ:GILD) voted against a proposal asking the company to disclose risks related to its drug pricing strategies.The proposal, put forth by the UAW Retiree Medical Benefits Trust, …

    Published on 5/7/2015
  • COMPANY NEWS: J&J enlists NYU to evaluate compassionate use requests

    Johnson & Johnson (NYSE:JNJ) said New York University School of Medicine will establish the Compassionate-Use Advisory Committee (CompAC), an independent committee to help the company evaluate compassionate use requests…

    Published on 5/7/2015
  • COMPANY NEWS: Management tracks

    Immunotherapy play Surface Oncology Inc. (Cambridge, Mass.) named Detlev Biniszkiewicz president and CEO. Biniszkiewcz was VP of oncology strategy at AstraZeneca plc (LSE:AZN; NYSE:AZN).Cancer play Ziopharm Oncology Inc…

    Published on 5/7/2015
  • COMPANY NEWS: MorphoSys acquires Lanthio

    MorphoSys AG (Xetra:MOR; Pink:MPSYF) said it will acquire all the shares it does not already own of Lanthio Pharma B.V. (Groningen, the Netherlands) for EUR 20 million ($22.3 million). MorphoSys, which invested in …

    Published on 5/7/2015
  • COMPANY NEWS: Regeneron anticipates "gradual" PCSK9 launch

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) signaled it expects "an initial gradual uptake at launch" for Praluent alirocumab to treat high cholesterol. A BLA for the PCSK9 inhibitor from Regeneron and Sanofi (Euronext…

    Published on 5/7/2015
  • COMPANY NEWS: CAFC delays launch of Zarxio

    The U.S. Court of Appeals for the Federal Circuit (CAFC) granted a motion from Amgen Inc. (NASDAQ:AMGN) for a preliminary injunction against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that will delay the launch…

    Published on 5/6/2015
  • COMPANY NEWS: Gilead acquires EpiTherapeutics

    Gilead Sciences Inc. (NASDAQ:GILD) acquired epigenetics company EpiTherapeutics ApS (Copenhagen, Denmark) for $65 million in cash, subject to undisclosed adjustments.EpiTherapeutics is developing preclinical small …

    Published on 5/6/2015
  • COMPANY NEWS: GSK opts to retain ViiV stake

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said in its 1Q15 earnings announcement that it will retain its holding in ViiV Healthcare, its HIV-focused joint venture with Pfizer Inc. (NYSE:PFE) and Shionogi & Co. Ltd. (Tokyo…

    Published on 5/6/2015
  • COMPANY NEWS: Juno meets its Fate in enhanced T cell therapy deal

    Fate Therapeutics Inc. (NASDAQ:FATE) jumped $2.28 (46%) to $7.24 on Wednesday after partnering with oncology company Juno Therapeutics Inc. (NASDAQ:JUNO). Fate will screen its library of small molecules to seek …

    Published on 5/6/2015
  • COMPANY NEWS: Management tracks

    H. Lundbeck A/S (CSE:LUN) named Kare Schultz president and CEO, effective May 20. Schultz was president and COO at Novo Nordisk A/S (CSE:NVO; NYSE:NVO). He replaces Ulf Wiinberg, who resigned in November 2014.Endocrine …

    Published on 5/6/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993